$1.39
4.79% yesterday
Nasdaq, Nov 15, 09:49 pm CET
ISIN
US02262M3088
Symbol
ALZN
Sector
Industry

Alzamend Neuro Inc Stock price

$1.36
-0.31 18.56% 1M
-4.84 78.06% 6M
-7.54 84.72% YTD
-13.64 90.93% 1Y
-342.14 99.60% 3Y
-2,023.64 99.93% 5Y
-2,023.64 99.93% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.10 6.85%
ISIN
US02262M3088
Symbol
ALZN
Sector
Industry

Key metrics

Market capitalization $6.53m
Enterprise Value $5.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-7.37m
Free Cash Flow (TTM) Free Cash Flow $-6.12m
Cash position $1.19m
EPS (TTM) EPS $-10.69
P/E forward negative
Short interest 5.21%
Show more

Is Alzamend Neuro Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Alzamend Neuro Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Alzamend Neuro Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Alzamend Neuro Inc:

Buy
100%

Financial data from Alzamend Neuro Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jul '24
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
67% 67%
-
-0.05 -0.05
67% 67%
-
- Selling and Administrative Expenses 2.98 2.98
57% 57%
-
- Research and Development Expense 4.30 4.30
49% 49%
-
-7.32 -7.32
52% 52%
-
- Depreciation and Amortization 0.05 0.05
67% 67%
-
EBIT (Operating Income) EBIT -7.37 -7.37
52% 52%
-
Net Profit -7.39 -7.39
52% 52%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alzamend Neuro Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Tampa, FL.

Head office United States
CEO Stephan Jackman
Employees 7
Founded 2016
Website www.alzamend.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today